Werewolf Therapeutics, Inc.
HOWL
$0.86
-$0.06-6.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.14M | 1.89M | 3.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 1.14M | 1.89M | 3.39M |
| Cost of Revenue | 36.53M | 37.31M | 37.85M | 37.56M | 31.95M |
| Gross Profit | -36.53M | -37.31M | -36.71M | -35.67M | -28.57M |
| SG&A Expenses | 23.68M | 24.30M | 24.73M | 24.94M | 24.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.61M | 73.01M | 75.57M | 75.48M | 69.59M |
| Operating Income | -71.61M | -73.01M | -74.42M | -73.59M | -66.21M |
| Income Before Tax | -72.84M | -73.14M | -72.41M | -70.52M | -62.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.84 | -73.14 | -72.41 | -70.52 | -62.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.84M | -73.14M | -72.41M | -70.52M | -62.12M |
| EBIT | -71.61M | -73.01M | -74.42M | -73.59M | -66.21M |
| EBITDA | -69.93M | -71.28M | -72.65M | -71.78M | -64.38M |
| EPS Basic | -1.62 | -1.64 | -1.64 | -1.63 | -1.50 |
| Normalized Basic EPS | -1.01 | -1.03 | -1.02 | -1.01 | -0.93 |
| EPS Diluted | -1.62 | -1.64 | -1.67 | -1.65 | -1.52 |
| Normalized Diluted EPS | -1.01 | -1.03 | -1.01 | -1.01 | -0.92 |
| Average Basic Shares Outstanding | 180.09M | 177.99M | 176.53M | 173.31M | 165.40M |
| Average Diluted Shares Outstanding | 180.09M | 177.99M | 177.05M | 173.83M | 165.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |